IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection.

ABSTRACT: IL15 is a key cytokine for the activation and survival of anti-tumor effectors CD8⁺ T and NK cells. Recently published preclinical studies demonstrate that the therapeutic activity of IL15 requires conventional dendritic cells type 1 (cDC1). Radiotherapy cooperates with IL15 by enhancing cDC1 tumor infiltration via interferon type 1 activation.

SUBMITTER: Pilones KA 

PROVIDER: S-EPMC7466855 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature